Published: July 01, 2005

Leerink Swann & Company Initiates Coverage of Cardiome Pharma Corporation (NASDAQ: CRME)

Share With Friends

Yesterday after the close, Senior Biotechnology Analyst, Joseph P. Schwartz, initiated coverage of Cardiome Pharma Corporation with an Outperform rating. Cardiome has three products in its pipeline, and Mr. Schwartz's rating is based on the potential success of Intravenous RSD1235, an agent for treating patients with atrial fibrillation. Survey work by MEDACorp supports Mr. Schwartz's finding that significant physician demand exists for this potential product, and Mr. Schwartz believes emerging news flow should enhance investor appreciation for Cardiome stock.

About Cardiome Pharma Corp.

Cardiome Pharma Corp. (NASDAQ: CRME) is a product-focused cardiovascular drug development company with three clinical drug programs, two of which focus on atrial arrhythmia and one is directed congestive heart failure. The company is headquartered in Vancouver, British Columbia.

About Leerink Swann & Company

Leerink Swann & Company is an investment banking firm that provides healthcare equity research, corporate finance, and asset management services for institutional and high-net-worth clients. Leerink Swann & Company was voted the Best Firm in Biotechnology, Medical Supplies and Devices, Pharmaceuticals/Major and Pharmaceuticals/Specialty in the December 2004 Institutional Investor poll ranking the best boutique and regional firms by sector. Through its consulting affiliate, MEDACorp, Leerink Swann & Company provides biomedical-consulting services to Life Sciences companies and to the institutional investment community. MEDACorp includes thousands of biomedical professionals and practicing physicians. Leerink Swann & Company is a member NASD/SIPC.